Brick & Kyle Associates’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Brick & Kyle Associates’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,300	Closed	-$51K	–	392
2017 Q1	$51K	Hold	1,300	–	–	0.04%	172
2016 Q4	$29K	Buy	1,300 +400	+44%	+$7.81K	0.02%	233
2016 Q3	$20K	Sell	900 -500	-36%	-$11.7K	0.02%	277
2016 Q2	$33K	Hold	1,400	–	–	0.03%	216
2016 Q1	$29K	Hold	1,400	–	–	0.03%	219
2015 Q4	$72K	Buy	1,400 +500	+56%	+$24.2K	0.06%	141
2015 Q3	$38K	Sell	900 -900	-50%	-$43.4K	0.04%	191
2015 Q2	$82K	Hold	1,800	–	–	0.07%	141
2015 Q1	$68K	Buy	1,800 +200	+13%	+$6.87K	0.06%	154
2014 Q4	$45K	Buy	+1,600	New	+$44.5K	0.04%	186

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Brick & Kyle Associates's PTLA Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 1,300 shares — an estimated $51K sold.

Brick & Kyle Associates first reported a position in PTLA in Q4 2014 and held it in 10 quarters. The position peaked at $82K in Q2 2015. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

Brick & Kyle Associates reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 1,300 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $51K.
Brick & Kyle Associates first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's Portola Pharmaceuticals, Inc. position peaked at $82K in Q2 2015.
206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.